Abstract:AIM:To develop a fusion vaccine of esophageal carcinoma cells and dendritic cells (DC) and observe its protective and therapeutic effect against esophageal carcinoma cell line 109 (EC109).METHODS:The fusion vaccine was produced by fusing traditional polyethyleneglycol (PEG), inducing cytokine, sorting CD34+ magnetic microbead marker and magnetic cell system (MACS). The liver, spleen and lung were pathologically tested after injection of the fusion vaccine. To study the therapeutic and protective effect of the fusion vaccine against tumor EC109, mice were divided immune group and therapeutic group. The immune group was divided into P, E, D and ED subgroups, immunized by phosphate buffered solution (PBS), inactivated EC109, DC and the fusion vaccine respectively, and attacked by EC109 cells. The tumor size, weight, latent period and mouse survival period were recorded and statistically analyzed. The therapeutic group was divided into four subgroups: P, inactivated EC109, D and ED subgroups, which were attacked by EC109 and then treated with PBS, inactivated EC109, DC, and EC109-DC respectively. Pathology and flow cytometry were also used to study the therapeutic effect of the fusion vaccine against EC109 cells.RESULTS:Flow cytometry showed that the expression of folate receptor (FR), EC109 (C), DCs (D) in human nasopharyngeal carcinoma cell line (HNE1) (B) was 78.21%, 89.50%, and 0.18%, respectively. The fusion cells (C) were highly expressed. No tumor was found in the spleen, lung and liver after injection of the fusion vaccine. Human IgG was tested in peripheral blood lymphocytes (PBL). In the immune group, the latent period was longer in EC109-DC subgroup than in other subgroups, while the tumor size and weight were also smaller than those in ED subgroup. In the therapeutic group, the tumor size and weight were smaller in ED subgroup than in P, inactivated EC109 and DC subgroups.CONCLUSION:Fusion cells are highly expressed not only in FR but also in CD80. The fusion vaccine has a distinctive protective effect against tumor EC109 and can inhibit the growth of tumor in mice, and its immune protection against tumor attack is more significant.

The anti-tumor effect of breast cancer fusion protein vaccine HSP65-HER2 in combination with CpG684

Vaccination with A Dna Vaccine Based on Human Psca and Hsp70 Adjuvant Enhances the Antigen-Specific Cd8(+) T-Cell Response and Inhibits the Psca(+) Tumors Growth in Mice

A Cpg Oligodeoxynucleotide Potentiates the Anti-Tumor Effect of Hsp65-Her2 Fusion Protein Against Her2 Positive B16 Melanoma in Mice

Antitumor therapeutic effect induced by intestine- carcinoma cells vaccine expressing membrane- bound heat shock protein 70

Antitumor Effect of Immunizations with Fusions of Dendritic and Hepatocellular Carcinoma Cells in Mice

Effect of tumor vaccine prepared by fusion of gastric cancer cells with dendritic cells

The Fusion Protein of Hsp65 with Tandem Repeats of Beta-Hcg Acting As A Potent Tumor Vaccine in Suppressing Hepatocarcinoma

Immunization with a HSP65–HER2 Fusion Peptide Selectively Eliminates HER2+ B16 Melanoma Cells in a Xenograft Tumor Mouse Model

Preliminary study on antitumor effect of C215gene transfected tumor vaccine and monoclonal antibody-superantigen fusion protein C 215Fab-SEA

Anti-tumor Effect and Its Mechanism of Co-Administration of Fusion Proteins Hvegf121/βhcg and Mgm-Csf/βhcg

Study of therapeutic adjuvant-free protein vaccine-HPV16Z-Hsp65-E6/E7

In Vivo Anti-Tumor Effect of Hybrid Vaccine of Dendritic Cells and Esophageal Carcinoma Cells on Esophageal Carcinoma Cell Line 109 in Mice with Severe Combined Immune Deficiency.

Improved efficacy of DNA vaccination against breast cancer by boosting with the repeat beta-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65.

Primary Screening of Antitumor Immunoadjuvants Combined with Heat Shock Fusion Protein

Antitumor Activity of Mhsp65-Ttl Enhanced by Administration of Low Dose Cyclophosphamide in Pancreatic Cancer-Bearing Mice

Enhancement of HSP-MUC1 Antitumor Activity by Type C CpG-ODN BW005

Comparison of fusion protein and DC vaccine in inhibition of mouse B16F10 melanoma tumor

Synergistic Tumoricidal Effect of Combined Hpd-L1 Vaccine and HER2 Gene Vaccine.

Experimental Study of Antitumor Immunity of DC/C6 Fusion Vaccine

Anti-tumor Effect of Tumor Vaccine Combined with Metronomic Chemotherapy on Breast Cancer in Mice

The experimental study of antitumor immunity of fusion vaccine of dendritic cell